,
Pharma Regulatory Services in Greece – Overview
Greece operates within the EU pharmaceutical regulatory framework, with the National Organization for Medicines (EOF) serving as the national competent authority. While marketing authorizations are obtained through EU-wide or coordinated procedures, successful entry and maintenance in Greece require careful management of national administrative requirements, local implementation steps, and post-authorization obligations.
Depending on product scope and strategy, sponsors may include Greece through the Centralized Procedure or via Decentralized, Mutual Recognition, or National Procedures. In addition to regulatory approval, Greece involves country-specific considerations across labeling, pharmacovigilance, serialization, pricing and reimbursement coordination, and national lifecycle management, all of which must be aligned to EU decisions and timelines.
Freyr supports sponsors in navigating Greece-specific regulatory execution, ensuring EU approvals are translated efficiently into national authorization, launch readiness, and sustained compliance.
Authorization pathways in Greece
- Centralized Procedure (CP):
EU/EEA-wide authorization granted via EMA and the European Commission, with Greece included and requiring national implementation and launch activities. - Decentralized Procedure (DCP):
First-time approvals across multiple Member States, with Greece participating as a Reference or Concerned Member State. - Mutual Recognition Procedure (MRP):
Extension of an existing national authorization to Greece through coordinated recognition. - National Procedure (NP):
Single-country authorization administered by EOF for products outside EU-wide or multi-state strategies.
Freyr Expertise – Pharma Regulatory Services in Greece
- eCTD authoring, compilation, publishing, technical validation, and submission for CP, DCP/MRP, and Greece national routes, including variations, renewals, and line extensions.
- Greece-specific route-to-market execution, including RMS/CMS coordination, national phase planning, and alignment with EOF procedural and administrative expectations.
- Clinical trial regulatory support under EU CTR, including CTIS submissions, EOF and National Ethics Committee coordination, RFI management, and site activation support.
- National Module 1 authoring for Greece, including administrative forms, legal declarations, fee coordination, and authority correspondence.
- Product information, labeling, and artwork management, including QRD-compliant SmPC, PL, and labeling texts, Greek translations, blue box requirements, Braille compliance, and mock-up coordination.
- Pharmacovigilance and safety operations for Greece, including local PV contact support, RMP updates, PSUR/PBRER coordination, and implementation of EU safety decisions at the national level.
- Support for serialization and supply readiness under the EU Falsified Medicines Directive (FMD), including NMVO onboarding and packaging alignment.
- Lifecycle management covering variations, renewals, labeling updates, and national implementation of EU regulatory changes to ensure continuity of supply.
Post-approval and lifecycle management
All authorization routes in Greece operate under EU pharmacovigilance, quality, and safety frameworks, with national oversight by EOF. Ongoing obligations include safety reporting, timely implementation of variations, maintenance of approved labeling and artwork, and coordination of pricing and reimbursement submissions where required.
Freyr supports continuous compliance in Greece by coordinating national lifecycle activities within broader EU strategies, ensuring regulatory changes are implemented efficiently and without disruption to market supply.
Engaging with Freyr enables efficient market entry, strong national phase execution, and sustained regulatory compliance in Greece as part of EU and multi-country launch strategies.
Want to know more about our Regulatory support in Greece